HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

MASS

908 Devices Inc. (NASDAQ)

Healthcare — Medical Devices

908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable FTIR device that rapidly detects and identifies approximately 28,000 unknown gas, vapor, powder, and liquid chemical hazards; ProtectIR, a handheld FTIR device that can identify approximately 23,000 solid and liquid chemical hazards; and VipIR, a handheld 3-in-1 analyzer that integrates FTIR, Raman spectroscopy, and smart spectral processing (SSP), a proprietary algorithm, to provide a single result from just one sample. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Burlington, Massachusetts.

None 2 analysts
$8.88
+$0.18 (+2.07%)
Target: $11.00 (23.9%)
Sign in to add MASS to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$335.78M
P/E Ratio (TTM)-
Forward P/E-30.98
EPS (TTM)$-0.97
Dividend Yield-
Profit Margin-62.40%
Revenue Growth13.60%
ROE-24.11%
Debt/Equity3.33
Recommendation None
Analyst Target$11.00
Analysts2
Indexes NASDAQ

Technical Indicators

RSI (14)71.9
Beta0.64
SMA 20-
SMA 40-
52-Week High$9.34
52-Week Low$5.03
50-Day Avg$7.87
200-Day Avg$7.01
Avg Volume296.4K
Volume245.8K

Performance Analysis

NEUTRAL

MASS presents a mixed picture with both positive and negative indicators.

+ Showing strength at 89% of its 52-week range.
- RSI at 71.9 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
~ Modest revenue growth of 13.6% year-over-year.
- Operating at a loss with -62.4% margin.
~ Wall Street consensus is "none" from 2 analysts.
+ Average analyst target of $11.00 implies 23.9% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:19 UTC

Back to Screener Export Report